MBRX Moleculin Biotech, Inc.
$0.72▼ -13.85%
Healthcare
Other
After hours
$0.73▲ +2.60%
Sep 11, 7:25 PM ET
Volume 1.92M
Avg Volume (10D) 584.9K
Key Metrics & Fundamentals
Market Cap
$13.93M
P/E Ratio
0.0
Div Yield
–%
52W Range
0.16 - 15.75
% vs 50 MA
-40.83%
% vs 200 MA
-74.77%
RSI-14
42.5
MACD Histogram
+0.0700
Beta (1Y vs SPY)
0.97
Free Cash Flow
-$6.66M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$7.54M
COGS
–
Operating Exp
$7.56M
Operating Income
-$7.56M
EBIT
-$7.56M
Pretax Income
-$7.64M
Net Income
-$7.64M
EPS (Diluted)
-1.40
Price & Volume History
Loading chart…
Recent News
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
GlobeNewswire · Sep 11, 2026 12:30 PM
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
GlobeNewswire · Aug 27, 2026 1:01 PM
Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why
Zacks · Aug 24, 2026 4:00 PM
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
GlobeNewswire · Aug 14, 2026 12:30 PM
Moleculin Announces Pricing of $9.3 Million Public Offering
GlobeNewswire · Jul 31, 2026 2:12 PM
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
GlobeNewswire · Jul 31, 2026 12:10 PM
Moleculin Biotech Files Registration Statement for Public Offering; Shares Fall
MT Newswires · Jul 29, 2026 2:36 PM
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
GlobeNewswire · Jul 6, 2026 12:33 PM
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance
Stocktwits · Jun 30, 2026 6:52 PM
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
GlobeNewswire · Jun 30, 2026 12:30 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See MBRX's money flow as a full page
Social Sentiment
No Reddit posts found for MBRX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.